文章预览
Suzhou, July 10, 2024-Kintor
Pharmaceutical Limited (“Kintor Pharma”, HKEX: 9939), announced that after receiving the designation for its in-house
developed KX-826 from the International Nomenclature Cosmetic Ingredient (the “INCI”), the Company’s cosmetics with KX-826 as the main ingredient was
officially launched into the international market recently. The first product is
the topical anti-hair loss solution for
androgenetic alopecia (the “AGA”). The Company will further explore the efficacy of
KX-826 in the field of AGA and acne, actively enrich the product lines, increase
market promotion to target users and meet customer requirements under different
usage scenarios. The Company is of the view that the launch of the New Product will provide a solid stream of revenue and cash flow
to the Group, benefiting the Group as a whole in the long term. KX-826 is one of the core innovative products of the
Group. During the course of its development, it has been used to comp
………………………………
